BMY
NYSEBristol-Myers Squibb Company
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks87+20%
2026-03-012026-08-23
Mix3090d
- Other11(37%)
- Insider9(30%)
- SEC Filings5(17%)
- Earnings3(10%)
- Dividends1(3%)
- Analyst1(3%)
Latest news
25 items- PRU.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First RelapseApproval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb’s targeted protein degradation platform Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of thera
- PRAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE:BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration. "Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies," said Kathleen Gallagher, Pres
- PRBristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, TexasNew State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS’ $40 Billion Commitment to American Innovation, Manufacturing and Economic Growth Bristol Myers Squibb (NYSE:BMY) today announced the selection of Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients. The campus, at Generation Park in Houston, will create nearly 500 skilled jobs and is designed to grow in scale, capability and workforce for decades to come. This press release
- ANALYSTBristol-Myers upgraded by Argus with a new price targetArgus upgraded Bristol-Myers from Hold to Buy and set a new price target of $75.00
- INSIDEREVP,Chief Med Offr,Head of Dev Massacesi Cristian converted options into 51,172 shares and covered exercise/tax liability with 26,175 shares (SEC Form 4)4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDEREVP, General Counsel Gallman Cari covered exercise/tax liability with 543 shares and converted options into 1,061 shares, increasing direct ownership by 4% to 13,649 units (SEC Form 4)4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- SECSEC Form 10-Q filed by Bristol-Myers Squibb Company10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
- SECBristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
- PRBristol Myers Squibb Reports Second Quarter Financial Results for 2026Bristol Myers Squibb (NYSE:BMY) today reported second quarter 2026 financial results. Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed second quarter 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:15 a.m. ET today, July 30, 2026, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives T
- PRBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIAExpanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines Bristol Myers Squibb (NYSE:BMY, "BMS")), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned NVIDIA infrastructure in life sciences. The e
- PRU.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple MyelomaApplication based on results from SUCCESSOR-2 trial showing oral CELMoD mezigdomide in combination with carfilzomib and dexamethasone significantly improved progression-free survival vs. standard of care in this patient population The U.S. FDA has assigned a target action date of May 13, 2027 Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM). Mezigdomide is an oral cereblon E3 ligase modulator, or CELMoD, for the treatment of multiple myeloma. The FDA has granted
- INSIDERSEC Form 4 filed by Director Yale Phyllis R4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDERSEC Form 4 filed by Director Samuels Theodore R. Ii4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDERSEC Form 4 filed by Director Rice Derica W4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcmullen Michael R.4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDERSEC Form 4 filed by Director Arduini Peter J4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- PRThe Quest to Repair What Multiple Sclerosis Takes AwayAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (profile) is determin
- PRBristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:15 a.m. ET. Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com. Materials related to the call will be available on the company's Investor Relations website prior to the start of the conference call. A replay of the webcast will be available here approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol M
- PRBristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on August 3, 2026, to stockholders of record at the close of business on July 2, 2026. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit
- INSIDERDirector Haller Julia A exercised 20,460 shares at a strike of $53.76, increasing direct ownership by 150% to 34,079 units (SEC Form 4)4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- INSIDEREVP, Corporate Affairs Short Bartie Wendy converted options into 8,040 shares and covered exercise/tax liability with 3,876 shares, increasing direct ownership by 53% to 12,081 units (SEC Form 4)4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- SECSEC Form 11-K filed by Bristol-Myers Squibb Company11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
- SECSEC Form 11-K filed by Bristol-Myers Squibb Company11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
- SECSEC Form 11-K filed by Bristol-Myers Squibb Company11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
- PRIzalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell CarcinomaInterim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO® 2026 SystImmune and Bristol Myers Squibb's potent dual-targeted EGFRxHER3 bispecific antibody-drug conjugate has now demonstrated clinical benefit in three Phase 3 trials in China, underscoring its broad therapeutic potential in multiple tumor types SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE:BMY) today announced that SystImmune's parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), reported positive results from prespecified interim analyses of two Phase 3 studies evaluating izalontamab brengitecan (iza-bren),
BMY FAQ
6 questionsWhat does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and...Where does BMY stock trade?
Bristol-Myers Squibb Company (BMY) is listed on NYSE.What sector and industry is BMY in?
Bristol-Myers Squibb Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BMY?
Bristol-Myers Squibb Company has had 8 recent analyst actions on file. The most recent action was from Argus: Buy on 2026-08-05. Recent price targets range from $4200.00 to $4500.00.What companies are similar to BMY?
Notable peers in the same industry include JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG), AZN (AstraZeneca PLC). Compare BMY side-by-side with any of them on Quantisnow.How can I track BMY on Quantisnow?
Quantisnow aggregates Bristol-Myers Squibb Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BMY to receive live email and push alerts on every new disclosure.